Engflag

Zasten

Quick links to important sections

Zasten

Zasten_EN

Method of action: Antiallergic, Anti-Asthmatic, Antihistamines For Systemic Use, Membrane Stabilizing, Ophthalmologic Agent, Ophthalmologicals

Treatment option: Allergic Conjunctivitis, Asthma, Atopic Dermatitis, Bronchitis, Dermatitis, Skin Conditions, Hives, Fever, Seizure Prophylaxis, Rhinitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zasten

Quick Facts: Zasten (Ketotifen Fumarate)

Property Description
Active Ingredient Ketotifen Fumarate
Pharmacological Class Mast cell stabilizer and H1-receptor antagonist
Origin Synthetic benzocycloheptathiophene derivative
Primary Forms Oral preparations (tablets, syrup) and ophthalmic solution (eye drops)
General Purpose Prophylactic (preventative) management of allergic responses

What Type of Medicine is Zasten (Ketotifen Fumarate)?

Zasten is a synthetic medicinal agent defined by its unique dual classification as both a Mast cell stabilizer and an Antihistamine, containing the single active ingredient Ketotifen Fumarate. As a benzocycloheptathiophene derivative, its pharmacological action is highly specific, targeting the chemical cascade of allergic reactions. The compound is classified as a Histamine H1 Inhibitor and anti-allergic agent, a role clinically recognized for its importance in allergic response management. This dual mechanism—blocking the effects of histamine while also preventing its release—distinguishes its identity from antihistamines designed only for acute, rapid symptom reversal. Clinical reviews confirm that Ketotifen's primary role as a mast cell stabilizer provides long-term preventive benefits for allergic conditions. The research indicates that the medicine is highly effective in providing sustained, preventative relief from common allergic triggers.

Composition and Available Forms of Zasten

The therapeutic efficacy of Zasten rests entirely on its active component, Ketotifen Fumarate, making it a single-ingredient product utilized in both systemic and topical applications. For systemic effects, the drug is typically formulated as oral preparations, including tablets and syrup, which are absorbed internally to modulate allergic responses across the body. Alternatively, Zasten is available as an ophthalmic solution (eye drops) for local/topical use, where the active ingredient is delivered directly to the eye's surface via a sterile aqueous vehicle. Ketotifen is authorized for human use, with verified stability and efficacy in its various forms. The medicine is characterized by a verified quality and safety profile regarding its composition.

The General Benefit of Zasten's Unique Mechanism

The general purpose of Zasten is to reduce the body's overall baseline reactivity to allergens by stabilizing the immune cells responsible for triggering allergic responses. This stabilization of mast cells decreases their propensity to spontaneously release inflammatory mediators such as histamine, thus interrupting the allergic response at its source. By performing both this cell-stabilizing action and the H1-receptor antagonist action, the medicine helps to minimize the frequency and severity of allergic reactions over time, supporting sustained, prophylactic anti-allergic activity. For instance, in seasonal allergy management, the proactive benefit of Zasten is widely documented, supporting a more stable and symptom-reduced period during high pollen exposure.

Regulatory References

  1. European Medicines Agency (EMA) medicine finder

What side effects are possible with Zasten?

Possible Side Effects and Safety Information

The safety profile for Zasten (Ketotifen Fumarate) is formally categorized by regulatory authorities, distinguishing between common reactions and rare, serious events. Adverse reactions are grouped by the affected physiological system, known as System-Organ Classes (SOCs), consistent with official labeling.

Frequency-Classified Adverse Reactions

Adverse events are generally mild and may occur with either the oral or ophthalmic formulations:

  • Common (1% to 10%): Drowsiness (somnolence), dry mouth, and headache are frequently reported, particularly with the oral form, or eye irritation and conjunctival injection (eye redness) with the ophthalmic solution. The initial drowsiness and dry mouth often resolve spontaneously with continued treatment, a time-related safety pattern noted in regulatory documents.
  • Uncommon (0.1% to 1%): Less frequent effects include dizziness, blurred vision, rash, or weight gain.

Serious Adverse Reactions and Safety Constraints

Although rare, the regulatory documentation specifies clinically important adverse reactions. These include occurrences of convulsions (seizures), which require caution in patients with a history of epilepsy, and severe, generalized hypersensitivity reactions. A specific caution exists regarding the oral form's concomitant use with oral antidiabetic agents due to a rare reported risk of thrombocytopenia (low platelet count).

Population-Specific Considerations

The safety profile includes constraints for specific groups. For the ophthalmic solution, safety has not been established in children below the age of 3 years. For the oral form, symptoms of Central Nervous System (CNS) stimulation, such as irritability, are noted as being especially likely to occur in children. Additionally, the syrup formulation contains carbohydrates, which is a consideration for patients with diabetes mellitus.

Overdose and Emergency Response

Zasten Overdose and when to seek help

The official regulatory documents for Zasten (Ketotifen Fumarate) detail the specific clinical manifestations and required emergency actions in case of systemic overdosage. The information establishes the scope of risks associated with the substance.

Overdose Scope

Category Official Regulatory Documentation
Documented Presentations Overdosage may present with Central Nervous System (CNS) depression, observed as drowsiness progressing to severe sedation, along with cognitive effects such as confusion and disorientation. Cardiovascular signs include tachycardia (abnormally fast heartbeat) and hypotension (low blood pressure).
Severe Outcomes The official labeling documents the potential for convulsions (seizures) and the occurrence of reversible coma following acute overexposure.
Population Notes Hyperexcitability and an increased risk of convulsions are explicitly noted to occur especially in children during an overdosage event.
Emergency Actions Regulatory agencies require individuals to seek immediate medical attention and contact a Poison Control Center right away if overdosage is suspected or confirmed.

Resulting Overdose Structure

Official Overdose Statements:

  • The management strategy is symptomatic and supportive. No specific antidote is known or documented in the official label.
  • Treatment may include considering procedures such as emptying of the stomach or administering activated charcoal if the exposure was very recent, as part of the initial supportive care protocol.

The established overdose profile defines the risks as severe neurological and cardiovascular instability. The official guidance mandates immediate engagement with emergency services for supportive care due to the lack of a specific antidote, with special consideration given to the documented pediatric risk factors.

Therapeutic Uses of Zasten

What Zasten Treats: Main Uses and Benefits

Zasten (Ketotifen Fumarate) is primarily utilized for its long-term, prophylactic role in managing chronic allergic and inflammatory conditions across conditions presenting with systemic or localized discomfort. The primary therapeutic benefit contributes to easing the overall symptom load of recurrent and disruptive symptoms.

Zasten is commonly used to help manage symptoms associated with allergic conjunctivitis, allergic rhinitis (hay fever), chronic urticaria (hives), and as a long-term strategy for mild atopic asthma. It may be applied in addressing symptom clusters such as those related to inflammatory or irritative states affecting the eyes and nose, as well as symptoms that create noticeable physiological strain, like whealing and pruritus. Zasten may be part of symptomatic management during phases when symptoms become more noticeable.

This makes it relevant for chronic disease management, seasonal prophylaxis, and supportive relief in systemic mast cell disorders.

Quick Fact: Relief for Recurrent Allergic Discomfort

Feature Therapeutic Focus
Main Use Prophylactic management of allergic manifestations
Key Symptoms Ocular itching, rhinorrhea, whealing, pruritus
Benefit Assists with maintaining functional stability
Context Chronic, recurrent, and episodic allergic states

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zasten

The eligibility for Zasten (Ketotifen Fumarate) is defined by regulatory agencies based on age, physiological status, and specific pre-existing conditions.

Eligibility Scope Official Regulatory Statement
Populations for whom use is allowed Approved for adults and children ge 3 years of age for the ophthalmic solution.
Populations for whom use is contraindicated Individuals with a known hypersensitivity to Ketotifen or any of the product's inactive ingredients.
Age-related eligibility rules Safety and effectiveness of the ophthalmic solution have not been established in children younger than 3 years of age.
Condition-specific eligibility rules The oral forms are used with caution or are restricted in patients with a history of epilepsy or seizure disorders.
Pregnancy and lactation eligibility status Use during pregnancy is generally not recommended due to insufficient human data. Use of the ophthalmic solution during breastfeeding is typically considered acceptable due to limited systemic absorption.
Eligibility-related restrictions Patients wearing soft contact lenses must remove the lenses before instilling the ophthalmic solution and wait a specified time (e.g., 10 minutes) before reinserting them.

Official Eligibility Classifications

The regulatory basis for eligibility relies on formal classifications such as Contraindicated (absolute exclusion) and Use Not Established (lack of sufficient data). These constraints define who is eligible, who is excluded due to a known risk (hypersensitivity, epilepsy), and which groups require conditional use (contact lens wearers). These statements establish the specific population boundaries for the safe use of the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic Potentiation and Systemic Constraints

The interaction profile for Zasten (Ketotifen Fumarate) is primarily structured around documented risks of pharmacodynamic potentiation with the systemic (oral) formulation. Regulatory documents note that co-administration with other antihistamines or CNS depressants (including sedatives and anxiolytics) may potentiate their effects, resulting in additive activity.

Consumption of alcohol is formally documented in official labeling to potentiate the effects of the medicine. A critical regulatory restriction is the requirement to avoid simultaneous use with oral antidiabetic agents. This combination has been associated in official reports with a documented risk of a reversible fall in the thrombocyte count.

Administration Timing and Substance Constraints

For the ophthalmic solution, the interaction profile involves specific administration timing rules. When Zasten eye drops are co-administered with any other ophthalmic drops, health authorities mandate an interval of at least 5 minutes between applications. If an eye ointment is part of the regimen, the ointment must be applied last.

Population-specific caution is associated with the syrup formulation, which contains carbohydrates. This is a factor requiring consideration for patients managing Diabetes mellitus or following a medically prescribed low-sugar diet.

Mechanism of Action

How Zasten Works

Zasten (ketotifen) primarily works by engaging several distinct but related mechanistic domains to modulate physiological responses associated with excessive mediator activity, influencing pathway activity toward an altered state.

Receptor-Mediated Signaling Modulation

Zasten acts as a non-competitive antagonist at the H1 histamine receptor (H1). This engagement directly suppresses the immediate signaling cascade initiated by histamine binding, resulting in the attenuation of rapid physiological responses elicited by histamine signaling at the H1 receptor.

Mast Cell and Basophil Stabilization

The compound modulates pathways within mast cells and basophils, the primary cellular sources of inflammatory mediators. By engaging mechanisms influencing intracellular calcium flux within these cells, the compound modulates the release of stored mediators, including histamine and leukotrienes. This inhibition of mediator secretion reduces the local concentration of proinflammatory agents in the tissue microenvironment.

Suppression of Early Molecular Steps

Zasten initiates sequences that modify early molecular steps in the inflammatory cascade, influencing systems where specific signaling patterns can rapidly escalate. This effect is thought to involve the suppression of certain cellular responsiveness. This modulation of early signaling steps results in altered downstream physiological responses and shifts in pathway activity.

Dosage and Administration Information

How to Use Zasten: Official Administration Guidelines

Zasten (Ketotifen Fumarate) is administered according to distinct instructions for its two approved routes, which define its use in systemic prophylaxis and localized topical application. All usage patterns and dosages are based on standard prescribing information.

Administration Routes and Dosing Regimens

Administration Route Standard Adult Dose Frequency Pediatric Rules
Oral (Tablets/Syrup) 1 mg Twice daily (BID) 1 mg BID for children 3 years and older; 0.05 mg/kg BID for children 6 months to 3 years.
Ophthalmic (Eye Drops) One drop in the affected eye(s) Twice daily (BID) Same as adult dose for children 3 years and older.

Use Protocol and Contextual Requirements

Oral Zasten is intended for prophylactic use, meaning treatment must be continued for a minimum of two to three months to accurately assess the full intended effect. This long-term usage pattern contrasts with medicines used for rapid, acute symptom reversal. Dosing is typically taken with or without food; however, it is standard practice to take the dose with morning and evening meals for consistent timing.

The medicine's use protocol also dictates the administration conditions for specialized forms and populations. If treatment is to be discontinued, the oral dosage must be progressively reduced over a two- to four-week period. For ophthalmic use, a key procedural constraint is the requirement to remove soft contact lenses before instilling the eye drops, with reinsertion permitted after 10 to 15 minutes to adhere to official administration guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The information is descriptive and does not constitute medical advice or a recommendation for use.

Mechanisms of Action Investigated

Studies have investigated the active ingredient, ketotifen fumarate, for its potential interaction with specific neurochemical pathways, particularly those relating to sensory signal processing. The compound is described as a non-competitive histamine H1 receptor antagonist and a mast cell stabilizer. Research has explored the hypothesis regarding the compound's effect on neurotransmitter activity and the inhibition of inflammatory mediator release.

Efficacy Data from Key Trials

Clinical trials, including randomized, double-masked, placebo-controlled studies, primarily investigated the endpoint of ocular itching associated with allergic conjunctivitis. Secondary outcomes examined the impact on conjunctival redness, tearing, and swelling. Results from the major Phase 3 trials generally reported a statistically significant difference in ocular itching scores compared to placebo at various time points after allergen challenge.

Safety and Tolerability Profile

Phase 3 data reported the incidence of adverse events (AEs) in the studied patients. Common adverse events reported in the study included headache, mild burning/stinging of the eyes, and dry mouth. These events were typically rated as mild to moderate in severity, and their course was tracked, as documented in the trial data.

Comparative Research

Early studies compared the outcomes associated with the compound against previous-generation anti-allergic treatments. These head-to-head designs focused on differences in the onset of effect (time to relief) and the frequency of adverse events reported over the treatment period. Comparative trials reported findings regarding the relative outcomes of different anti-allergic agents in managing symptoms.

Frequently Asked Questions (FAQ)

Common questions about Zasten (FAQ)

Q: What is Zasten, and what is it used for?

Zasten contains the active substance ketotifen, which is an antiallergic and an asthma prophylactic medication. It is used to help prevent and treat allergic symptoms.

Key indications include:

  • Prevention and treatment of allergic rhinitis (hay fever) and other allergic reactions affecting the skin or other parts of the body.
  • It is used in adults and children from 6 months of age.

Q: Is Zasten used to treat an acute asthma attack?

No, Zasten is not used to treat an acute or sudden asthma attack. It is a long-term preventive treatment for allergic symptoms. If you have an acute asthma attack, you should use your fast-acting rescue inhaler as prescribed by your doctor.

Q: How does Zasten work?

Zasten works by reducing the body's response to allergens (substances that cause allergic reactions). The active ingredient, ketotifen, is an antihistamine and a mast cell stabilizer. It works by:

  1. Blocking histamine (a chemical released during allergic reactions).
  2. Inhibiting the release of other inflammatory substances from certain cells (mast cells) that contribute to inflammation and asthma symptoms.

It helps to reduce the frequency and severity of allergic symptoms over time.

Q: How long does it take for Zasten to start working?

It is important to understand that Zasten's full benefit is not immediate. It may take several weeks of regularly taking this medication before you notice the full reduction in your symptoms. Therefore, you must continue to take it exactly as prescribed, even if you do not feel an immediate effect.

Q: What are the common side effects of Zasten?

The most common side effect is drowsiness (feeling sleepy or less alert), especially when starting the treatment. This usually lessens over time. Other common side effects may include:

  • Slight dizziness
  • Dry mouth
  • Increased appetite or weight gain
  • Nervousness or irritability (especially in children)
  • Trouble sleeping (sleep disturbances)

If these effects are severe or bothersome, discuss them with your doctor or pharmacist. Drowsiness/reduced alertness is a key side effect to be aware of; use caution when performing activities that require concentration until you know how this medication affects you.

How should Zasten be stored and disposed of?

How to Store and Dispose of Zasten?

Official regulatory guidelines define specific conditions necessary to maintain the stability and safety of Zasten (Ketotifen Fumarate).

Storage and Handling Requirements

Requirement Official Instruction
Temperature Store at room temperature, typically below 25 C or 30 C.
Environmental Protection Keep protected from light and moisture. Do not refrigerate or freeze the medicine.
Container & Access Keep Zasten in its original, closed container. Store securely out of the sight and reach of children.
Post-Opening Stability Liquid forms, such as the syrup or eye drops, must be discarded after 4 weeks of opening.

Disposal Rules

Unused or expired Zasten must not be thrown into household waste or poured down the drain. Disposal must be conducted according to local pharmaceutical waste regulations, often requiring return to a pharmacy or an approved collection point. This is a mandatory measure to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSpain

Equivalent of Zasten found in:

A-Z Index: